**Discontinuation of Last-Resort Antibiotic Recarbrio Ignites Funding Discussion** By Rachel Brazil Published on October 12, 2026 The recent cessation of the antibiotic combination Recarbrio by Merck & Co has rekindled debates on the financial measures needed to ensure the continued access to essential yet rarely utilized medications. The halt of Recarbrio’s production occurs despite its […]
Read More